Summary Background: While autonomic neuropathy has been reported in chronically hypoxaemic patients of chronic obstructive pulmonary disease (COPD), whether it also occurs in patients with milder disease and in those without chronic hypoxaemia has not been explored.
Introduction
Chronic hypoxaemia has been postulated as a mechanism for the development of peripheral neuropathy 1 in diabetes mellitus. An increased incidence of peripheral neuropathy has also been observed in chronic obstructive pulmonary disease (COPD) and may be related to chronic hypoxaemia. 2 Indeed, electrophysiological abnormalities have been reported to be much more common 3, 4 than clinically manifest neuropathy.
Autonomic neuropathy is another well-recognized complication of diabetes mellitus. It is important as it has been implicated in sudden cardiorespiratory arrest. 5 Unlike diabetes mellitus, the occurrence of autonomic neuropathy has received much less attention in COPD. It was first reported in chronically hypoxaemic patients by E-mail address: skchhabra@mailcity.com (S.K. Chhabra).
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Stewart et al. 6 in 1991. They observed definite autonomic dysfunction in 35% and evidence of early autonomic neuropathy in another 47% of patients and it was attributed to chronic hypoxaemia. Its significance remains undefined as there were no clinical manifestations.
Findings of autonomic neuropathy unresponsive to short-term oxygen treatment were reported later by Hjalmarsen et al. 7 This suggests that either the neuropathy may not relate to the presence of hypoxaemia or may be an irreversible process. It is also possible that the autonomic neuropathy in COPD is not a complication but an independent process that runs in parallel with other physiological changes. It implies that it should be possible to detect its presence even in milder cases of COPD. This has not been explored earlier. We therefore carried out the present study to assess autonomic cardiovascular function in patients with a wider spectrum of clinical severity, from mild-to-severe. In addition to the severity of airways obstruction and abnormalities of arterial blood gases, its relationship with echocardiographically measured mean pulmonary artery pressure (MPAP), another commonly affected physiological parameter in COPD, was also investigated.
Methods
Fifty-six patients, all males and diagnosed as having COPD were included in this prospective study carried out in the outpatient setting in a tertiary referral hospital, Vallabhbhai Patel Chest Institute, Delhi. Eleven age-matched healthy non-smoker subjects served as the controls. The study was approved by the Institutional Review Committee. Informed consent was taken.
The diagnosis of COPD was based on the criteria of the British Thoracic Society 8 and established by a history of smoking greater than 20 pack-years, cough with expectoration accompanied by progressively increasing dyspnoea on exertion. Asthma was excluded clinically. Only stable patients requiring no change in their medication in the previous 4 weeks and not having had an acute exacerbation in that period were included. The inclusion criteria included an FEV 1 /FVC ratio of less than 70% and a post-bronchodilator increase in FEV 1 of less than 12% and 200 ml from the initial value. The severity of COPD was categorized on the basis of FEV 1 % predicted as per the British Thoracic Society Criteria 8 : mild (above 60%), moderate (40-59.9%) and severe (less than 40%). Patients with clinical cor pulmonale, congenital, rheumatic or any valvular heart disease, systemic hypertension, coronary artery disease and any other past or concurrent pulmonary disease, diabetes mellitus, renal failure, carcinoma, connective tissue disorder and liver disease were excluded clinically and by biochemical tests where relevant. None of the patients consumed alcohol on a regular basis or had any dietary deficiency of vitamins (B group) or had any disease such as malabsorption that could cause vitamin deficiency. These patients were not on any medication other than that required for control of COPD. These drugs included inhaled bronchodilators (salbutamol and ipratropium bromide) and corticosteroids (budesonide, beclomethasone or fluticasone).
The investigations were carried out in the morning between 10 AM and 12 noon. The patients were asked not to take bronchodilators 12 h before the tests. Inhaled corticosteroids were allowed in the same dosage as being already taken. A light breakfast was permitted at least 2 h before the tests.
Spirometry was performed on dry, rolling-seal spirometer of the Transfer Test C model lung function machine (P.K. Morgan, Kent, UK). Maximal expiratory flow volume (MEFV) curves were obtained. Three acceptable and at least two reproducible curves were obtained in each subject. The highest FEV 1 obtained was recorded. Reference equations for north Indian adults were used to calculate the percent-predicted values. 9 Single breath carbon monoxide diffusion capacity (DLCO SB ) was measured on the same apparatus and corrected for alveolar volume to obtain transfer factor ðT L COÞ: Arterial blood gas analysis was carried out on a sample drawn from the radial artery in a heparinzed glass syringe and measured in Instrumentation Laboratory machine (Model 1312). Echocardiographic assessment was done by using all standard echocardiographic windows (parasternal long-axis view, parasternal short-axis view, apical four chamber view, subcoastal view). Following M-mode and 2-D assessment of morphology, color flow mapping was done to identify the pulmonary and tricupsid regurgitant jets. A pulsed doppler study was next applied to confirm and localize the above regurgitant jets and then, continuous wave doppler study was done to record their maximum velocity. Mean pulmonary artery pressure (MPAP) was calculated from the right-ventricular outflow tract flow acceleration time using the Mahan's equation. 10 Autonomic function was assessed by tests of cardiovascular reflexes. 11 These are simple, reliable, non-invasive and reproducible. The tests were carried out in a quiet and comfortable room with the temperature maintained around 25-281C. The heart rate responses were obtained from a standard lead II strip recording on an ECG machine while the blood pressure (BP) was measured using a mercury sphygmomanometer. The heart rate responses test the parasympathetic function while the BP response tests the sympathetic function. The following test were done:
Heart rate response to valsalva maneuver
The patient rested for 5 min in a sitting position. Then, after a moderate inspiration, the patient performed a Valsalva maneuver by blowing into a mouthpiece connected to a modified sphygmomanometer with a column-holding pressure of 40 mm of Hg for 15 s during which a continuous ECG was recorded. The patient then breathed normally for a minute. The heart rate was recorded as inverse of the RÀR interval. The results were expressed as Valsalva ratio, which is ratio of the longest RÀR interval after release from the maneuver to the shortest RÀR interval during the maneuver. The maneuver was performed three times. The mean of three values was taken as the final value. It was ensured that maximal inspiration was not taken as that lowers the values. A value o1:10 was taken as abnormal, 1.11-1.12 as borderline and X1:13 as normal.
11
Heart rate variation during deep breathing
The patient was seated and performed six deep breaths over a 1-min period. The maximum and minimum RÀR interval during each breathing cycle were measured and converted to beats per minute. The result was expressed as the difference of heart rate during inspiration and expiration (I-E difference). Normally, heart rate falls during expiration. Patients with an autonomic neuropathy lose this variability. An I-E difference o11 beats/min was taken as abnormal, 11-14 as borderline and X15 as normal.
Heart rate response to postural change
The patient was asked to lie supine for 3 min. Then he was then asked to rise rapidly and unaided to a standing position. In a normal response, the heart rate is maximal at the 15th beat and minimum around the 30th beat. The shortest RÀR interval at or around the 15th beat and longest RÀR interval around the 30th beat after starting to stand was measured. The heart rate response was expressed as the 30:15 ratio. Patients with autonomic neuropathy have a heart rate that continues to rise through this observed time. An average of three readings was taken. A value o1.01 was taken as abnormal, 1.01-1.03 as borderline and X1.04 as normal. On the basis of the responses, the patients were categorized as follows: (i) No autonomic neuropathy: all responses in the normal range; (ii) early autonomic neuropathy: one test abnormal; (iii) definite autonomic neuropathy: two or more abnormal tests.
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Statistical analysis was done with the help of SPSS 9.0 software for Windows and GraphPad Prism 3.0 for windows. Deviations from gaussian distribution were tested using the Kolmogorov-Smirnov (KS) test. After ascertaining the normality, the autonomic responses were compared between the three groups of severity of COPD using the analysis of variance (ANOVA). If ANOVA revealed significant differences among groups, inter-group comparisons were done using the Bonferroni's test to identify the significantly different groups. Baseline characteristics in the three groups were compared similarly. Comparisons between patients and normals, and between patients with and without hypoxaemia were made using unpaired Student's t-test. Proportions of patients with normal, borderline and abnormal responses, and absent, early and definitive autonomic neuropathy in the three groups of COPD were compared using the Chisquare test. Co-efficients of correlation in bivariate relationships were obtained using the Pearson's correlation test. A ''P'' value of o0.05 was considered as statistically significant.
Results
The mean7SD age of COPD patients was 57.9679.81 while that of the normal subjects was 50.8279.82. Thirteen patients had mild, 17 had moderate and 26 had severe COPD. The body mass index (BMI) of patients and controls was similar (22.4174.81 and 22.3674.45, respectively, P40:05). The characteristics of the patients are given in Table 1 . The patients in the three groups of COPD differed significantly for BMI, FEV 1 %pre-dicted, PaO 2 , PaCO 2 , and MPAP (ANOVA). Bonferroni test revealed patients with severe COPD to have significantly lower BMI, FEV 1 %predicted, PaO 2 and higher PaCO 2 , and MPAP compared to mild COPD (Po0:05 for all paired comparisons). Table 2 shows the frequency of normal, borderline and abnormal responses to each of the tests of autonomic function in patients and normal subjects. Among patients, majority of the test responses were in the abnormal or borderline range except for the 30:15 ratio for which 64% had normal responses. The highest proportion of patients with abnormal responses was observed for the IE difference followed by the valsalva ratio. Among normals, more than 90% of test responses were in the normal or borderline range with occasional abnormal response. Among patients, only 12 (21.4%) had no evidence of autonomic neuropathy while 16 (28.6%) had early neuropathy and 28 (50%) had definite neuropathy. Among normals, 7(64%) had no evidence of autonomic neuropathy while 4(36%) had early neuropathy. No normal subject had evidence of definite neuropathy.
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The valsalva ratio, was significantly greater in normal subjects as compared to that in the patients with COPD ðPo0:01Þ: Similarly, the 30:15 ratio and the IE difference was also greater in the former as compared to the latter group ðPo0:05Þ: The BP response to postural change was less in the former group as compared to the latter ðPo0:05Þ: These data are shown in Figs 1a and b. Table 3 shows the coefficients of correlation between FEV 1 % predicted, PaO 2 , PaCO 2 , T L CO; and MPAP, and tests of autonomic function. Significant correlations were observed between both FEV 1 % predicted and PaO 2 , and the responses to all tests of autonomic function except for the IE difference. The 30:15 ratio and BP responses to posture change also had a significant relationship with T L CO while the valsalva ratio was also significantly related to the MPAP. Figure 2a shows the valsalva and 30:15 ratios in patients with mild, moderate and severe COPD compared using ANOVA. The valsalva ratio differed significantly among the three groups ðPo0:01Þ: Between-group comparisons revealed the response in severe COPD patients to be significantly different from both the mild and the moderate group ðPo0:01Þ while the latter two groups did not differ between themselves ðP40:05Þ: The 30:15 ratio was also significantly different among the three groups ðPo0:01Þ: Between group comparisons showed that the severe group patients had significantly different responses as compared to the mild group ðPo0:05Þ; the other between-group comparisons not being different ðP40:05Þ: Figure 2b shows the IE difference and BP response to postural change in patients with mild, moderate and severe COPD compared using ANOVA. The IE difference in the three groups was not significantly different ðP40:05Þ: However, the BP response to postural change was significantly different in the three groups ðPo0:01Þ: While the responses were not different between severe and moderate COPD patients, both the groups had significantly greater change in BP than that observed in the mild group (Po0:01 and 0.05, respectively). Table 4 shows a comparison of responses to tests of autonomic function in patients with and without hypoxaemia. The differences were significant only for the BP response to postural change ðPo0:01Þ: Among patients with hypoxaemia, 5 (12.8%) had no evidence of autonomic neuropathy while 10 (25.6%) had early neuropathy and 24 (61.5%) had definite neuropathy. Among those without hypoxaemia, 7 (41.2%) had no evidence of autonomic neuropathy while 6 (35.3%) had early neuropathy and 4 (23.5%) had definite neuropathy. These proportions were significantly different ðPo0:05Þ: Table 5 shows the responses to tests of autonomic function according to severity of COPD. The proportions of patients with normal, borderline and abnormal responses were not significantly different for Valsalva ratio and IE difference while these were different 30:15 ratio and BP responses to posture change. For the latter two tests, the proportion of subjects with normal responses were greater in those with mild COPD while borderline or abnormal responses were more frequent in the moderate or severe disease. Figure 3 shows the proportions of subjects with absent, early and definite neuropathy in different groups of COPD severity. These proportions were significantly different ðPo0:05Þ:
Discussion
The present study shows that cardiovascular autonomic neuropathy is common in COPD. Although it tended to be observed more often in patients with moderate and severe COPD, a fair proportion of patients with mild COPD were also observed to have this abnormality. Similarly, while it was more prevalent in patients with hypoxaemia, it was also found to occur in those without hypoxaemia. The responses to tests of autonomic function had a significant relationship with FEV 1 % predicted and PaO 2 , but the strength of correlation was weak.
The role of hypoxaemia in the pathogenesis of autonomic neuropathy is not clear. While Sterwart et al. 6 included only hypoxaemic subjects in their study, our patients had a wider clinical spectrum. An important finding in our study is that chronic hypoxaemia is not necessary for its occurrence. The group means differed only for the BP response to postural change when patients with and without hypoxaemia were compared. While definite neuropathy was more frequent among those with hypoxaemia, early/definite neuropathy was observed in as many as 10 out of 17 patients without hypoxaemia. It has been shown that administration of oxygen does not reverse the abnormal autonomic responses. 7 This could also imply that the neurological changes are irreversible. However, a role for hypoxaemia cannot still be ruled out as repeated episodes of transient hypoxaemia that may occur during sleep, exercise or acute infective exacerbations may be important. We cannot rule out such episodes of transient hypoxaemia in our patients without chronic hypoxaemia.
The relationship of autonomic neuropathy with severity of COPD appears to be weak. In the study by Stewart et al. 6 the correlation coefficients were moderately strong only between Valsalva ratio and PaO 2 (0.66), Valsalva ratio and FEV 1 (0.56), 30:15 ratio and PaO 2 (0.51) and 30:15 ratio and FEV 1 (0.51). The correlations between other tests and FEV 1 or PaO 2 were weak or nonsignificant. In the present study with patients having a wider clinical spectrum, these correlations were also weak. Except for the IE difference, the other tests showed significantly greater changes from the normal range in patients with moderate or severe disease as compared to those with mild COPD. The proportions of patients with normal, borderline and abnormal responses were not significantly different for the Valsalva ratio and IE difference between the three groups of clinical severity while for 30:15 ratio and BP responses to posture change, the proportion of subjects with normal responses were greater in those with mild COPD while borderline or abnormal responses were more frequent in the moderate or severe disease. These results suggest that although abnormalities are more likely to be observed in those with moderate or severe disease, these may also be found in those with mild COPD. This coupled with the observation of abnormal responses in patients without chronic hypoxaemia suggest that autonomic neuropathy may be an early phenomenon in the natural history of COPD.
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Our results suggest that autonomic neuropathy in COPD has no causative relationship with the severity of airway obstruction and hypoxaemia but is an independent abnormality that develops gradually and progressively and thus runs parallel with other markers of disease severity. This would also explain the weak but significant correlations observed between T L CO; MPAP and the responses to some of the tests of autonomic function. The abnormality in the reflexes used to assess cardiovascular autonomic responses could lie in the receptors, the afferent pathway, the center, the efferent pathway or the effector organ. This requires investigation.
The clinical significance of these observations and the previous documentation of autonomic neuropathy is that it may carry a grave prognosis as in diabetes mellitus 12 putting the subject at the risk of sudden cardiac death. Tentolouris et al. 13 have shown that QTc prolongation is associated with major degrees of autonomic neuropathy in diabetics. Stewart et al. 6 have also postulated a role for autonomic dysfunction in the salt and water retention in COPD. Although none of our patient complained of symptoms that could arise because of autonomic dysfunction, symptoms such as giddiness or palpitations that some patients of COPD do complain of or the occurrence of arrythmias may have a basis in this.
We excluded other possible causes of neuropathy in our patients, clinically or by biochemical tests where relevant. Patients with diabetes mellitus, renal failure, carcinoma, connective tissue disorders and liver disease were excluded. None of the patients consumed alcohol on a regular basis or had any dietary deficiency of vitamins (B group) or any disease such as malabsorption that could cause vitamin deficiency. The body mass was similar to the control group. Thus, we are certain that the observed changes in autonomic function were due to COPD itself.
In conclusion, cardiovascular autonomic neuropathy is common in COPD and should be documented. Its pathogenesis, clinical significance and natural history remain to be established. Figure 3 Proportions of subjects with absent, early and definite neuropathy in groups of COPD according to severity.
